Researchers at Harvard have teamed up with Mercia to design a next-generation Alzheimer's disease vaccine. The beta-amyloid-targeted formulation features an adjuvant that promotes a beneficial anti-inflammatory response that the team hopes will enhance beta-amyloid clearance without triggering neuroinflammation.